Vázquez-Ortíz G, Piña-Sanchez P, Hidalgo A, Lazos M, Moreno J, Alvarado I, Cruz F, Hernández DM, Pérez-Plascencia C, Salcedo M

Idioma: Español
Referencias bibliográficas: 30
Paginas: 434-441
Archivo PDF: 247.95 Kb.

RESUMEN

La infección por virus de papiloma de alto riesgo (VPH) es considerada como el factor etiológico más importante del cáncer cérvico uterino (CaCU). Con el fin de determinar el patrón de expresión global e identificar algunos posibles genes marcadores del CaCU, se utilizaron microhileras de DNA que contenían 8,000 secuencias que codificaban para transcritos diferentes, para estudiar los perfiles de expresión de cinco líneas celulares derivadas de CaCU, tres muestras tumorales conteniendo VPH16 y tres muestras normales negativas para la presencia de VPH. Se identificaron los niveles de expresión de genes relacionados con diferentes rutas metabólicas. Se llevó a cabo el análisis de agrupamiento jerárquico y posteriormente se confirmó la sobrexpresión de dos genes mediante RT-PCR. Estos dos genes se encontraron sobrexpresados en biopsias tumorales cervicales. Uno de ellos, el gen de IL6, que ha sido previamente reportado en relación con CaCU, así como el gen de la matriz-metaloproteasa 10 (MMP10) por primera vez relacionado con esta neoplasia. El análisis de agrupamiento jerárquico, además, reveló que las muestras que contienen el mismo tipo viral están asociadas, sugiriendo posibles diferencias en expresión entre tipos virales.

REFERENCIAS (EN ESTE ARTÍCULO)

1. World Health Statistics, 1987-1990. World Health Organization.

2. Programa de prevención y control del cáncer cérvico-uterino. México: Secretaría de Salud; 1992.

3. Brisson J, Morin C, Fortier M, et al. Risk factors for cervical intraepithelial neoplasia: differences between low- and high-grade lesions. Am J Epidemiol 1994; 140: 700-10.

4. Castellsague X, Bosch F, Muñoz N. Environmental co-factors in HPV carcinogenesis. Virus Research 2002; 89: 191-9.

5. Schiffman M, Bauer H, Hoover R, Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993; 85: 958-64.

6. Munoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 2000; (1-2): 1-5.

7. Walboomers J, Jacobs M, Manos M, Bosch F, Kummer K, et al. Human Papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.

8. Bosch F, Lorincz A, Muñoz N, Meijer C, Shah K. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-65.

9. Lorincz A, Temple G, Kurman R, Jenson A, Lancaster W. Oncogenic association of specific human papilloma virus types with cervical neoplasia. J Int Cancer Inst 1987; 79: 671-7.

10. Choo KB, Chen CM, Han CP, Cheng WT, Au LC. Molecular analysis of cellular loci disrupted by papillomavirus 16 integration in cervical cancer: frequent viral integration in topologically destabilized and transcriptionally active chromosomal regions. J Med Virol 1996; 49: 15-22.

11. Münger K, Werness BA, Dyson N, Phelps WC, Howley PM. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 1989; 8: 4099–4105.

12. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-36.

13. Park T, Fujiwara H, Wright T. molecular biology of cervical cancer and its precursors. Cancer 1995; 76(Suppl): 1902-13.

14. Milde-Langosch K, Riethdorf S. Role of cell-cycle regulatory proteins in gynecological cancer. J Cell Physiol 2003; 196: 224-44.

15. Shyu JS, Chen CJ, Chiu CC, Huang SC, Harn HJ. Correlation of human papillomavirus 16 and 18 with cervical neoplasia in histological typing and clinical stage in Taiwan: an in-situ polymerase chain reaction approach. J Surg Oncol 2001; 78: 101-9.

16. Caceres-Cortes J, Alvarado-Moreno J, Waga K, Rangel-Corona R, Monroy-Garcia A, et al. Implication of tyrosine kinase receptor and steel factor in cell density-dependent growth in cervical cancers and leukemias. Cancer Res 2001; 61: 6281-9.

17. Eisen M, Spellman P, Brown P, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci 1998; 95: 14863-8.

18. Davies J, Garrod D. Molecular aspects of the epithelial phenotype. Bioessays 1997; 19: 699-704.

19. Ross D, Scherf U, Eisen M, Perou C, Rees C, Spellman P, Iyer V, Jeffrey S, Rijn M, Walthman M, Pergamenschikov A, Lee J, Lahkari D, Shalon D, Myers T, Weinstein J, Botstein D, Brown P. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genetics 2000; 24: 227-35.

20. Ahn WS, Bae SM, Lee JM, Namkoong SE, Han SJ, Cho YL, Nam GH, Seo JS, Kim CK, Kim YW. Searching for pathogenic gene functions to cervical cancer. Gynecol Oncol 2004; 93: 41-8.

21. Welsh J, Zarrinkar P, Sapinoso L, Kern S, Behling CA. Analysis of gene expression in normal and neoplasic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci 2001; 3: 1176-81.

22. Moscow J, Schenider E, Ivy S, Cowan K. Multidrug resistance Chemoter Biol Response Modif 1997; 17: 139-77.

23. Nguyen H, Hiscott J, Pitha P. The growing family of interferon regulatory factors. Cytokine Growth Factor Rev 1997; 8: 293-312.

24. Kishimoto T. The biology of Interleukin-6. Blood 1998; 74: 1-10.

25. Hoffman-Liebermann B, Liebermann DA. Supression of c-myc and c-myb is tightly linked to terminal differentiation induce by IL6 or LIF and not growth and no inhibition by myeloid leukemia cells. Oncogene 1991; 6: 903-9.

26. Rochter H, Holley R, Andrews W, Owen J, Miller K. The association of interleukin 6 with clinical and laboratory parameters of acute pelvic inflammatory disease. Am J Obstet Gynecol 1999; 181: 940-4.

27. Espevikn T, Wange S, Faxvaag A, Shalaby M. Regulation of interleukin-2 and interleukin-6 production from T-cells: involvement of interleukin-1 beta and transforming growth factor beta. Cell Immunol 1990; 126: 4756-61.

28. Tjiong M, van der Vange N, Kate F, Tjiong SP, Ter Shegget J. Increased IL-6 and IL-8 levels in cervicovaginal secretions of patients with cervical cancer. Gynecol Oncol 1999; 73: 285-91.

29. Eustace D, Han X, Gooding R, Riches P, Hyderman E. Interleukin-6 functions as an autocrine growth factor in cervical carcinoma in vitro. Gynecol Oncol 1993; 50: 15-9.

30. Gaiotto MA, Focchi J, Ribalta JL, Stavale JN. Comparative study of MMP-2 (matrix metalloproteinase 2) immune expression in normal uterine cervix, intraepithelial neoplasias, and squamous cells cervical carcinoma. Am J Obstet Gynecol 2004; 190: 1278-82.